Quality Assurance

InnoMedica obtained a license to manufacture and wholesale pharmaceuticals in accordance with GMP standards in 2014. Since the start of the phase I clinical study with the drug in the field of oncology in 2018, the intravenous drugs manufactured at the production facility in Marly have been used to treat cancer patients in Swiss hospitals. Dr. Caroline Dafflon-Urech and Philipp Steffen are jointly responsible for Quality Assurance, and along with their five-person team, ensure an effective quality system is maintained in accordance with GMP standards. They represent the final authority responsible for approving the batches for delivery to the hospitals, and are supported by Stéphane Gumy as the technically responsible person.

Dr. Maïa Caillier – PhD in Molecular and Cellular Biology, École Normale Supérieure de Lyon, previously: Manufacturing Engineer at STAAR Surgical
Dr. Caroline Dafflon-Urech – PhD in Oncology, EPFL; previously: PostDoc at Novartis Institutes for Biomedical Research (NIBR)
Dr. Iris Hug – PhD in Biochemistry and Molecular Biology, University of Bern
Philipp Steffen – Master of Science in Chemistry & Molecular Sciences, University of Bern; previously: Quality Management Validation at CSL Behring
Dr. Huiyuan Zhao – PhD in Biochemistry, University of Fribourg